The study orchestrated by Oshima, Takayama, Nakajima-Takagi, and colleagues deploys advanced single-cell ATAC-seq technology to map chromatin accessibility changes in hematopoietic stem and progenitor cells (HSPCs) isolated from patients with varying stages of MDS. These regulatory changes are crucial because chromatin accessibility directly influences transcription factor binding and gene expression, thus dictating cell fate and function. Previous studies had largely overlooked the dynamics of chromatin remodeling at the stem cell level in MDS, focusing instead on bulk populations of mature cells. This new angle sharpens the molecular resolution and provides insights into the earliest events driving disease onset and progression.

The authors found that as MDS evolves, there is a distinct and progressive alteration in chromatin accessibility profiles within stem cells. These alterations were not abrupt but manifested as a continuum of epigenetic reprogramming events, revealing that the disease process is marked by a gradual rewiring of gene regulatory networks. Notably, stem cells from MDS patients showed a diminished accessibility in genomic regions linked to hematopoietic differentiation, alongside enhanced accessibility in regions associated with inflammatory signaling and stress response pathways. This dual pattern suggests a pathological shift wherein stem cells progressively lose their normal differentiation potential while acquiring abnormal stress-adaptive traits that may promote clonal dominance and survival.

Central to the study’s findings is the identification of key transcription factor motifs whose binding sites were variably accessible along the disease trajectory. These motifs belong to regulatory players such as RUNX1, GATA2, and SPI1, all critical to hematopoietic stem cell maintenance and lineage commitment. The researchers demonstrated that the differential accessibility of these motifs correlates with transcriptional changes in corresponding target genes, highlighting an intricate epigenetic-transcriptional feedback loop. The disruption of this regulatory network likely contributes to the hematopoietic dysregulation seen in MDS, offering new candidate targets for precision medicine interventions.

Furthermore, the research delineates a clear distinction between early and advanced MDS based on chromatin features. Early MDS stem cells showed subtle yet distinct epigenomic alterations that may serve as early biomarkers of disease. In contrast, advanced-stage MDS cells exhibited widespread chromatin remodeling, culminating in global transcriptional chaos and loss of hematopoietic identity. This insight advances the field’s understanding of MDS heterogeneity and may guide risk stratification and prognosis in clinical settings.

Complementing the chromatin accessibility data, the study incorporates single-cell RNA sequencing to validate transcriptional outputs corresponding to epigenomic changes. This integrative approach strengthens the causal link between chromatin dynamics and gene expression programs that underlie disease phenotypes. The combined datasets also revealed unexpected activation of inflammatory signaling pathways within the stem cell compartment itself, reinforcing the emerging view that inflammation is not merely a secondary event but a driver of MDS pathogenesis.

Importantly, the team’s work underscores the plasticity and vulnerability of hematopoietic stem cells in the face of genetic and epigenetic insults. MDS mutations often affect epigenetic regulators, but the precise impact on chromatin architecture and how it disrupts normal hematopoiesis has remained unclear. By focusing on chromatin accessibility, the study offers a functional readout of how these mutations translate into altered regulatory landscapes, thereby connecting genotype to phenotype at a mechanistic level.

The implications of these findings are vast. Therapies that aim to restore normal chromatin accessibility or correct aberrant transcription factor binding patterns may hold promise in arresting or reversing MDS progression. The data also provide a framework for identifying patients at high risk of leukemic transformation by tracking epigenomic shifts in stem cells, enabling earlier and more effective therapeutic interventions. Moreover, this epigenetic roadmap can serve as a platform for screening drug candidates that modulate chromatin state or transcriptional machinery specifically in malignant stem cells.

While the study marks a significant leap forward, it also raises compelling questions for future research. How do specific mutations interact with the epigenomic environment to shape disease trajectory? Can these chromatin changes be modulated in vivo to restore normal hematopoiesis? And what role might the bone marrow niche and immune microenvironment play in reinforcing or mitigating these epigenetic alterations? Addressing these will be crucial to translating these mechanistic insights into effective therapies.

Interestingly, the progressive nature of chromatin remodeling unveiled here challenges the conventional notion of MDS as a static disorder. Instead, it should be viewed as a dynamic evolutionary process driven by iterative epigenetic and transcriptional changes. This conceptual shift underscores the importance of longitudinal monitoring of patients’ chromatin landscapes, potentially through minimally invasive assays in peripheral blood progenitors or circulating stem cells.

The study also illuminates the broader principle that chromatin accessibility profiling at single-cell resolution can unravel disease trajectories in complex clonal disorders beyond MDS. This methodological advance sets a precedent for dissecting epigenetic heterogeneity in other hematologic malignancies and solid tumors, fostering a more nuanced understanding of cancer evolution and resistance.

In summary, the research by Oshima et al. provides a captivating glimpse into the epigenetic underpinnings of myelodysplastic syndromes. By combining state-of-the-art single-cell techniques with rigorous computational analyses, the team paints a vivid picture of how stem cell chromatin landscapes progressively deteriorate, heralding disease onset and escalation. These findings not only deepen our biological understanding but also pave the way for novel diagnostic and therapeutic approaches aimed at intercepting MDS at its roots.

The meticulous work stands as a testament to the power of integrative genomics and epigenomics in unraveling the complex interplay between genetics, cell biology, and disease. As we move toward an era of precision medicine enriched with epigenetic insights, studies like this will be indispensable in crafting interventions that are both targeted and adaptable, fundamentally improving patient outcomes in MDS and potentially other malignancies derived from stem cell dysregulation.

Subject of Research: Chromatin accessibility and transcriptional changes in hematopoietic stem cells during progression of myelodysplastic syndrome.

Article Title: Chromatin accessibility in stem cells unveils progressive transcriptional alterations in myelodysplastic syndrome.

Article References:
Oshima, M., Takayama, N., Nakajima-Takagi, Y. et al. Chromatin accessibility in stem cells unveils progressive transcriptional alterations in myelodysplastic syndrome. Nat Commun 16, 10726 (2025). https://doi.org/10.1038/s41467-025-65753-5

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41467-025-65753-5

Hematopoietic stem cells are the cornerstone of blood production, with their ability to self-renew and differentiate essential for lifelong maintenance of the blood system. The promise of homology-directed repair (HDR)-based gene editing has been to provide permanent correction of inherited blood disorders by precisely rewriting disease-causing mutations in these cells. However, achieving this therapeutic vision has proven far more complicated and unpredictable than anticipated. After years of incremental progress, the fidelity and durability of edited HSPCs have remained suboptimal, showing impaired engraftment and loss of function after transplantation.

The meticulous investigations carried out at SR-Tiget now offer a mechanistic explanation: the combined use of CRISPR-Cas9 to generate targeted DNA breaks and AAV6 vectors as DNA repair template delivery vehicles activates robust cellular stress responses. These include a potent DNA damage response (DDR) largely orchestrated by p53 tumor suppressor pathways and a complex inflammatory cascade mediated by interleukin-1 (IL-1) and the transcription factor NF-κB. Together, these pathways push edited hematopoietic stem cells into a senescence-like state, a form of premature cellular aging marked by permanent cell cycle arrest and secretion of inflammatory factors.

This senescence induction is not merely a transient penalty for editing trauma but rather a lasting imprint that significantly diminishes the functional fitness of the cells over time. Dr. Di Micco explains, “We observed that a subset of gene-edited HSPCs display premature aging features that persist months after transplantation into recipient animals. This senescence undermines their capacity to repopulate and sustain healthy blood formation, threatening the long-term success of gene therapies aimed at durable cures.”

Drilling deeper, Dr. Anastasia Conti, first author and project leader in the Di Micco lab, emphasized the unexpected persistence of these detrimental effects. “Our data show that stem cells retain a ‘molecular memory’ of the gene editing process. They don’t simply recover from stress; they remain locked in a dysfunctional state that hampers their therapeutic potential. Understanding and mitigating these adverse consequences is paramount.”

This revelation shines light on previously unexplained setbacks encountered in recent clinical trials of HDR-based therapies for hematologic disorders. Despite promising in vitro efficacy, clinical outcomes often failed to deliver robust, long-lasting engraftment and correction. The new insights suggest that inflammatory and senescence pathways activated during editing lead to compromised stem cell competitiveness and exhaustion post-transplant.

Confronted with this challenge, the SR-Tiget team embarked on an innovative strategy to rescue the functional integrity of edited stem cells by modulating the deleterious stress responses. They tested two interventional approaches: transient inhibition of p53 signaling to blunt the DNA damage response and administration of anti-inflammatory agents targeting IL-1 signaling. Anakinra, a clinically approved IL-1 receptor antagonist, emerged as a particularly potent compound capable of attenuating inflammation and senescence markers.

Importantly, both strategies showed promise in preclinical models. The combined or individual use of p53 inhibitors and Anakinra significantly reduced cellular senescence phenotypes in edited HSPCs and improved their ability to engraft and sustainably regenerate a healthy, polyclonal hematopoietic system. Beyond preserving stem cell fitness, Anakinra also lowered the incidence of genotoxic side effects such as large-scale deletions and chromosomal rearrangements that can arise during gene editing, highlighting its safety advantages over p53 inhibition alone.

These findings carry profound implications for the future design of gene-editing therapies targeting blood diseases that require lifelong correction, including immunodeficiencies, bone marrow failure syndromes, and hemoglobinopathies. By integrating approaches to curb inflammatory and senescence responses triggered by the editing components, clinicians and researchers can now envision therapies with enhanced durability, efficacy, and safety.

The work also stresses the complex interplay between gene editing tools and intrinsic cell biology, reminding the field that cutting-edge molecular precision is only one piece of a larger puzzle involving stem cell stress, immune activation, and cellular aging processes. Such multifaceted understanding is necessary for translating promising lab discoveries into transformative cures.

Supported by prominent funding bodies such as the European Research Council and the New York Stem Cell Foundation, this research exemplifies the international effort to refine CRISPR-based platforms for clinical application. Dr. Luigi Naldini, director of SR-Tiget and a pioneer in gene therapy, remarks that these advances reaffirm SR-Tiget’s leadership in pushing the boundaries of gene-editing science toward safe, scalable medicine.

Ultimately, the study underscores the importance of balancing gene correction efficiency with maintenance of stem cell health, paving the way for next-generation personalized therapies that not only fix genetic defects but also preserve the vitality of the patients’ own regenerative cells. The integration of senescence mitigation measures is an essential evolution in gene-engineering protocols, ensuring that treatments provide lifelong benefit rather than transient improvement.

As gene editing technologies continue to evolve rapidly, this pioneering work serves as a necessary course correction by identifying hidden biological barriers and introducing practical countermeasures. It lays foundational knowledge that could be extended beyond hematopoietic cells to other tissues where similar stress and senescence phenomena may compromise therapeutic gene editing outcomes.

With this new clarity on the molecular underpinnings of gene editing-induced senescence and inflammation, the field is poised for a leap forward toward realizing the full potential of gene therapy. The convergence of precise genome engineering, refined vector delivery, and cellular stress modulation heralds a new era of regenerative medicine destined to transform lives of patients suffering from previously intractable blood disorders.

Subject of Research: Animals (hematopoietic stem and progenitor cells)

Article Title: Senescence and inflammation are unintended adverse consequences of CRISPR-Cas9/AAV6 mediated gene editing in hematopoietic stem cells

News Publication Date: 3-Jun-2025

Web References:

• San Raffaele Telethon Institute for Gene Therapy (SR-Tiget): https://research.hsr.it/en/institutes/san-raffaele-telethon-institute-for-gene-therapy.html
• European Research Council: https://erc.europa.eu/homepage
• European Innovation Council (X-PAND): https://www.xpand-project.eu/
• New York Stem Cell Foundation: https://nyscf.org/

References:

• Di Micco, R., Conti, A., et al. (2025). Senescence and inflammation are unintended adverse consequences of CRISPR-Cas9/AAV6 mediated gene editing in hematopoietic stem cells. Cell Reports Medicine. DOI: 10.1016/j.xcrm.2025.102157

Image Credits: San Raffaele-Telethon Institute for Gene Therapy

Keywords: CRISPR-Cas9, AAV6 vectors, hematopoietic stem cells, senescence, inflammation, gene editing, DNA damage response, p53 pathway, IL-1/NF-κB signaling, Anakinra, homology-directed repair, gene therapy, regenerative medicine

Osteopetrosis arises from inherited mutations that impair the resorptive activity of osteoclasts, specialized cells responsible for breaking down bone matrix to maintain healthy bone remodeling. The failure of osteoclast function disrupts the normal architecture of the BM niche, notably hampering the crucial homing and engraftment of HSPCs. This phenomenon leads to an accumulation of circulating HSPCs (cHSPCs) in peripheral blood due to their inability to properly populate the BM microenvironment, further exacerbating hematopoietic deficiencies. Early intervention is vital since progressive bone marrow failure severely limits treatment alternatives such as bone marrow transplantation.

Capitalizing on the window of opportunity presented shortly after birth, the novel LV gene transfer model strategically harnesses in vivo delivery of corrective genetic material directly into cHSPCs circulating in newborn osteopetrotic mice. This innovative approach bypasses the need for ex vivo manipulation of stem cells, aiming to restore gene function systemically by exploiting the natural trafficking dynamics of HSPCs during postnatal development. The methodology leverages engineered viral vectors adept at safely delivering therapeutic genes into target cells with high efficiency, integrating into the genome to allow sustained gene expression and cellular correction.

Experimental results demonstrate that in vivo LV-mediated gene therapy significantly extends the survival of osteopetrotic neonatal mice, a critical proof of concept indication that early postnatal genetic intervention can alter the disease trajectory. Gene-corrected HSPCs engrafted in vivo were shown to differentiate effectively into osteoclasts possessing functional bone resorption capacity. This functional recovery signifies a key milestone, as the restoration of osteoclast activity is essential for the remodeling of aberrant osteopetrotic bone and re-establishing a healthy BM microenvironment conducive to hematopoiesis.

Despite these encouraging outcomes, the study underlines that complete phenotypic rescue remains elusive within the parameters of the current experimental framework. The aggressive and rapidly progressing nature of osteopetrosis in this murine model imposes formidable challenges for full disease reversal. The findings underscore the critical need for optimization of gene transfer efficiency, vector design, and potentially combinatorial therapeutic strategies to achieve complete functional recovery in severe genetic bone diseases.

Intriguingly, the research highlights the mechanistic interplay between the impaired osteoclastogenesis inherent in osteopetrosis and the consequent perturbation of HSPC BM homing. Understanding this bidirectional crosstalk not only informs therapeutic targeting but also deepens the biological insight into how skeletal pathology intricately influences hematopoietic dynamics. These insights could have broader implications for other bone marrow niche disorders where cellular microenvironment and stem cell trafficking are disrupted.

The delivery of LV vectors in vivo shortly after birth presents a paradigm shift from conventional ex vivo gene therapy approaches, which often necessitate hazardous myeloablative conditioning and complex cell processing. By capitalizing on the natural postnatal mobilization of HSPCs into peripheral circulation, this method promises a less invasive, more readily translatable intervention that could be adapted for a spectrum of genetic diseases affecting blood and immune cells.

Furthermore, the robustness of this strategy was evaluated by detailed phenotypic analyses, showcasing the differentiation capacity of gene-corrected HSPCs into functional osteoclasts within the native BM microenvironment. Corrected osteoclasts demonstrated the ability to form resorption lacunae, a hallmark of their bone remodeling functionality, which is critical for reversing the osteopetrotic bone phenotype. This functional evidence consolidates the therapeutic relevance of early in vivo gene transfer for skeletal genetic disorders.

Nonetheless, the rapid disease progression and severity in this osteopetrotic mouse model presented significant obstacles, limiting the extent of therapeutic benefit achievable in a single intervention. Future research avenues include refining vector tropism and expression kinetics, enhancing transduction efficiency in target cells, and timing optimization to maximize the therapeutic window. The exploration of adjunctive agents promoting osteoclast differentiation or BM niche modulation may also amplify gene therapy efficacy.

These findings herald a new frontier in regenerative medicine by demonstrating that early postnatal in vivo gene therapy can penetrate systemically to correct a complex inherited disorder involving both hematopoietic and skeletal systems. They open avenues for clinical translation in treating patients with osteopetrosis and related conditions, aiming to circumvent the constraints posed by conventional therapies that rely heavily on donor availability and pre-conditioning regimens.

The comprehensive study provides a critical foundation for further development of postnatal gene therapy modalities that leverage stem cell trafficking patterns intrinsic to early life stages. It challenges the existing dogma requiring ex vivo manipulations and expands the therapeutic horizon for addressing congenital disorders with lethal or debilitating phenotypes manifesting soon after birth.

In conclusion, this research marks a transformative stride in understanding and harnessing postnatal hematopoietic stem cell biology for gene therapy, demonstrating significant survival benefits and partial phenotypic correction in a severe osteopetrosis mouse model. Continued investigation and technological refinements will be imperative to translate these promising preclinical results into viable clinical interventions that can change the lives of patients born with these devastating genetic diseases.

Subject of Research:
In vivo lentiviral-mediated gene therapy targeting hematopoietic stem and progenitor cells in an osteopetrosis mouse model to correct bone marrow failure and impaired osteoclast function.

Article Title:
In vivo haemopoietic stem cell gene therapy enabled by postnatal trafficking

Article References:
Milani, M., Fabiano, A., Perez-Rodriguez, M. et al. In vivo haemopoietic stem cell gene therapy enabled by postnatal trafficking. Nature (2025). https://doi.org/10.1038/s41586-025-09070-3

Image Credits: AI Generated

At the core of this research lies the elegant biology of stem cells, which possess the remarkable ability to differentiate into various specialized cell types, governed by tightly regulated genetic programs. The team’s challenge was to decode the complex genetic instructions that prompt a stem cell to commit specifically to a blood lineage. To tackle this, Dr. Bigas’ lab performed an unbiased, genome-wide screen in the murine model, systematically testing thousands of genes to identify those responsible for steering embryonic stem cells toward becoming hematopoietic progenitors. Their perseverance paid off when they uncovered a combination of seven critical genes that, when activated in a precise temporal manner, successfully reprogrammed mouse embryonic stem cells into HSPCs.

These newly induced HSPCs were not only phenotypically similar to natural blood stem cells but also demonstrated functional competence in vivo, as they engrafted in adult mice and regenerated a fully operational hematopoietic system. This system included the production of diverse blood cell lineages essential for immune defense, oxygen transport, and clotting. The functional validation of these lab-generated cells marks an essential milestone, proving that targeted gene activation can recapitulate the complexity of blood stem cell development, a feat that opens new therapeutic avenues.

Critically, the implications extend beyond mouse models. Dr. Bigas emphasizes the evolutionary conservation of these genes, noting their high sequence similarity across species, including humans. This conservation underpins the hypothesis that the mechanisms controlling stem cell fate and differentiation are fundamentally shared, suggesting that the mammalian blueprint revealed by this study could be applicable in human systems. Current efforts are underway to translate these findings to human embryonic stem cells, an essential step toward clinical application.

This breakthrough is part of a larger ERC synergy-funded initiative titled "Making Blood," which aspires to establish a cutting-edge platform capable of manufacturing human HSPCs on demand. Should this endeavor succeed, it could herald a new era in the treatment of blood-related disorders, where patients no longer require compatible donors for bone marrow transplantation—a procedure that often involves significant logistical and immunological challenges.

The research, recently published in the esteemed journal Blood, sheds light on the intricate gene regulatory networks that define hematopoietic fate decisions. By employing an unbiased genome-wide approach rather than relying on candidate gene trials, the team ensured a comprehensive and objective discovery process. Such thoroughness enhances the robustness of the findings and offers an expanded genetic toolkit for synthetic biology approaches aimed at blood regeneration.

Importantly, the study integrates developmental biology with translational medicine. Collaborations with experts in pediatric and developmental leukemia, Dr. Clara Bueno and Dr. Pablo Menéndez, have contextualized the importance of these genes in human disease, reinforcing the potential for targeted genetic manipulation to correct hematopoietic deficiencies or malignancies born from aberrant stem cell differentiation.

The potential of producing HSPCs ex vivo with precise genetic programming holds transformative promise for regenerative therapies, immune system reconstitution, and personalized medicine. It challenges current paradigms in transplantation biology, where matching donor and recipient immune profiles remains a critical barrier. By generating stem cells that can be tailored to individual patient needs, this technology could circumvent issues of compatibility and graft-versus-host disease.

The pathway forward, however, is complex. Translating murine genetic programs to human stem cells requires meticulous validation of gene function, timing, and expression levels, as minor deviations may result in incomplete or aberrant differentiation. Additionally, ensuring the safety and stability of genetically reprogrammed cells before clinical use is paramount, requiring comprehensive preclinical studies and regulatory scrutiny.

This work also highlights the synergistic power of interdisciplinary research centers such as the Josep Carreras Leukaemia Research Institute and the Hospital del Mar Research Institute, both recognized for excellence in biomedical science and translational research. Their combined expertise in hematology, oncology, stem cell biology, and clinical research facilitates rapid movement from bench to bedside, accelerating the development of novel therapies.

Funding from national and European scientific bodies, along with prestigious foundations, underscores the strategic importance placed on regenerative medicine for hematological disorders. Investment into projects like “Making Blood” reflects a broader commitment to harnessing the full potential of stem cells to address unmet clinical needs, including leukemia, anemia, and immunodeficiencies.

As research progresses, the scientific community remains vigilant but optimistic. Dr. Bigas’ group continues to unravel the complex genetic landscapes governing stem cell fate, poised to unlock further biological secrets and deliver therapeutic breakthroughs. Their work stands at the nexus of molecular biology, genetics, and clinical innovation, capturing imaginations and catalyzing hope among patients and researchers alike.

This landmark discovery revives the vision of producing a renewable source of healthy blood stem cells, potentially reshaping the management of hematological diseases. It paves the way for future innovations where laboratory-engineered cells could replace damaged or diseased marrow, offering cures where none existed before. The era of regenerative hematology may soon move from conceptual ambition to clinical reality.

Subject of Research: Cells

Article Title: An unbiased genomewide screen uncovers 7 genes that drive hematopoietic stem cell fate from mouse embryonic stem cells

News Publication Date: 10-Apr-2025

Web References:

• Blood Journal Article
• Josep Carreras Leukaemia Research Institute
• Bigas Lab Stem Cells and Cancer Research

References:
Luis Galan Palma, Gayathri M Kartha, Maria Maqueda, Mercedes Barrero, Eric Canton, Arnau Iglesias, Jessica Gonzalez Miranda, Patricia Herrero Molinero, Raul Torres-Ruíz, Bernhard Payer, Clara Bueno, Pablo Menendez, Lluis Espinosa, Anna Bigas; An unbiased genomewide screen uncovers 7 genes that drive hematopoietic stem cell fate from mouse embryonic stem cells. Blood 2025; blood.2024027742. doi: 10.1182/blood.2024027742

Image Credits: Credit: Hospital del Mar Research Institute

Keywords: Stem cells, Blood cells, Bone marrow cells, Bone marrow